Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Teva Pharmaceutical Industries Ltd receives CHMP positive opinion for DuoResp Spiromax for the treatment of patients diagnosed with asthma and COPD in Europe


Friday, 21 Feb 2014 07:50am EST 

Teva Pharmaceutical Industries Ltd:Says the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorization for DuoResp Spiromax.Says DuoResp Spiromax (budesonide & formoterol fumarate dihydrate) inhalation powder for the treatment of patients with asthma and chronic obstructive pulmonary disease (COPD) when a combination inhaled corticosteroid and long-acting beta2-adrenoceptor agonist is appropriate.Says this CHMP decision creates a path forward for a final approval decision from the European Commission that is expected in the next few months. 

Company Quote

58.0
1.35 +2.38%
19 Dec 2014